Ho Yeong Lim

Samsung Medical Center ORCID: 0000-0001-9325-2300

4

h-index

4

Publications

11,418

Citations

Publications

4 shown

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim , Răzvan Cristescu , Adam J. Bass +20 more

2018 Nature Medicine 1624 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

2019 The Lancet Oncology 1593 citations

Frequent Co-Authors

Richard S. Finn

UCLA Jonsson Comprehensive Cancer Center

Baek‐Yeol Ryoo

Asan Medical Center

Philippe Merle

Hôpital de la Croix-Rousse

Masatoshi Kudo

Kindai University

Mohamed Bouattour

Assistance Publique – Hôpitaux de Paris

В. В. Бредер

Russian Cancer Research Center NN Blokhin

Researcher Info

h-index: 4
Publications: 4
Citations: 11,418
Institution: Samsung Medical Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-9325-2300

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.